Research published in Journal of psychopharmacology (Oxford, England)

Functional connectivity alterations of the pregenual anterior cingulate cortex by ketamine and the modulation by lamotrigine.

Journal of psychopharmacology (Oxford, England) June 19, 2025 David Weigner, Marvin Sören Meiering, Anne Weigand et al.

Neuroimaging studies have linked the beneficial effects of subanaesthetic ketamine doses in psychiatric conditions characterized by chronic stress pathology (CSP) to altered functional connectivity (FC) within the pregenual anterior cingulate cortex (pgACC). Previous research indicates a potential role of glutamate concentration in FC changes; however, the precise relationship between glutamate...

DOI: 10.1177/02698811251346705 Full text Resting state Working memory Ketamine ketamine Mental health benefits +6

Naturalistic use of psychedelics is associated with longitudinal improvements in anxiety and depression during global crisis times.

Journal of psychopharmacology (Oxford, England) June 18, 2025 Maria Bălăeţ, William Trender, Annalaura Lerede et al. 2 citations

Mental health implications of COVID-19 drug use patterns are still unclear. We used data-driven clustering in a large citizen science cohort recruited agnostically to an interest in drug-use to categorise people according to common patterns of drug use and analysed their mental health symptoms (GAD-7 and PHQ-9 items), from recruitment prior to COVID-19 restrictions in 2020 (N = 242,260) to...

DOI: 10.1177/02698811251346729 Full text Well-being Reduced anxiety Reduced depression Improved mental health +5

A model training curriculum for psychedelic, psycholytic, and entactogen-assisted psychotherapy.

Journal of psychopharmacology (Oxford, England) June 10, 2025 Torsten Passie, Anja Loizaga-Velder, Alicia Danforth et al. 4 citations

The authors offer a model for curriculum for education and training in substance-assisted psychotherapy (SAP), that is, psychedelic, psycholytic, and entactogen/MDMA (3,4-methylenedioxymethamphetamine)-assisted psychotherapy, addressing both the detailed contents of training and the question of experiential training. All authors of this model have an abiding interest and extensive experience in...

DOI: 10.1177/02698811241282759 Full text Psychedelic therapy MDMA-Assisted Psychotherapy Education of therapists Psycholytic therapy +7

Six weeks open-label oral ketamine for patients with treatment-resistant depression, post-traumatic stress disorder, or obsessive-compulsive disorder.

Journal of psychopharmacology (Oxford, England) June 5, 2025 Ben Beaglehole, Paul Glue, Shona Neehoff et al. 19 citations

We previously completed a double-blind randomised crossover study assessing intramuscular ketamine for treatment-resistant depression (TR-D), post-traumatic stress disorder (TR-PTSD) and obsessive-compulsive disorder (TR-OCD). Here, we report an extension study to explore the ongoing benefits and tolerability of maintenance oral ketamine. All participants from the original study were eligible...

DOI: 10.1177/02698811251344710 Full text PTSD Depression Psychopharmacology Ketamine therapy +7

Effects of serotonergic psychedelics on synaptogenesis and immediate early genes expression - comparison with ketamine, fluoxetine and lithium.

Journal of psychopharmacology (Oxford, England) May 28, 2025 Yana Vella, Kateřina Syrová, Aneta Petrušková et al. 1 citation

Recent evidence suggests that psychedelics can induce rapid and long-lasting antidepressant effects. The generally acknowledged explanation for these traits is the phenomenon of neuroplasticity, although the exact underlying molecular mechanisms remain unclear. This study investigates the effects of psilocin, lysergic acid diethylamide (LSD) and N,N-dimethyltryptamine (DMT) on synaptogenesis...

DOI: 10.1177/02698811251338232 Full text DMT LSD Neuroplasticity Ketamine +5

What are set and setting: Reducing vagueness to improve research and clinical practice.

Journal of psychopharmacology (Oxford, England) May 26, 2025 Kyle Patch, William R. Smith 3 citations

Research on the therapeutic potential of psychedelics has surged, prompting a re-examination of the role of set and setting in psychedelic-assisted therapy. Yet, these concepts are vague and typically defined over inclusively. We believe that set and setting research should be methodologically reductionist, focusing on specific components rather than set and setting as such. To that end, we...

DOI: 10.1177/02698811251337372 Full text Psychedelics Philosophy of science Set and setting Psychedelic-therapy +4

Psychedelic-assisted psychotherapy: The need to monitor adverse events.

Journal of psychopharmacology (Oxford, England) May 21, 2025 Krj Schruers, N K Leibold

The therapeutic use of psychedelics for mental health issues holds considerable promise. However, systematic assessment of adverse events associated with these substances has received relatively little attention. Here, we discuss several considerations concerning the assessment of adverse events in psychedelic-assisted therapies. We discuss the preference for using the term "adverse effects"...

DOI: 10.1177/02698811251340929 Full text Psychedelic-assisted therapy Adverse events Hallucinogenic therapy Clinical safety +4

Are the LSD-analogs lisuride and ergotamine examples of non-hallucinogenic serotonin 5-HT2A receptor agonists?

Journal of psychopharmacology (Oxford, England) May 5, 2025 Jan Kehler, Morten Skøtt Thomsen Lindskov 3 citations

The recent resurgence of classical psychedelic compounds, specifically 5-HT2A receptor agonists, as potential therapeutics has led to numerous initiatives aimed at better understanding the mechanisms underlying their effects. Psychedelic compounds are commonly known as hallucinogens. One of the major outstanding questions in the field is whether altered states of consciousness-the...

DOI: 10.1177/02698811251330741 Full text LSD Serotonin Lisuride Psychedelics hallucinogens +6

Psychedelic risks and benefits: A cross-sectional survey study.

Journal of psychopharmacology (Oxford, England) May 1, 2025 Sean P. Goldy, Benjamin A Du, Julia S Rohde et al. 15 citations

As classic psychedelics' therapeutic potential is studied and their popularity continues to rise, it is important to establish their relative risks and benefits. Previous surveys have tended to use convenience sampling on social media, select participants who have had either extremely positive or negative effects, and have not compared the risk/benefit profile of psychedelics to other...

DOI: 10.1177/02698811241292951 Full text Cannabis Psychedelics Risks

Co-use of psychedelics with other substances: Findings from the global psychedelic survey.

Journal of psychopharmacology (Oxford, England) May 1, 2025 Stephanie Lake, Philippe Lucas 13 citations

While most psychedelic substances are considered to carry a relatively low risk of acute or long-term harm, co-use with other psychoactive substances may increase health and social harm. Using a large international survey of adults who use psychedelics, we sought to comprehensively characterize psychedelic co-use. We used data from the 2023 Global Psychedelic Survey, a web-based survey of...

DOI: 10.1177/02698811241292956 Full text Co-use Harm reduction International Psychedelics hallucinogens +6

Hemispheric annealing and lateralization under psychedelics (HEALS): A novel hypothesis of psychedelic action in the brain.

Journal of psychopharmacology (Oxford, England) May 1, 2025 Adam W. Levin 4 citations

Current models of psychedelic action in the brain propose changes along the dorsal-ventral and anterior-posterior axes but neglect to address the lateral axis. This article proposes a novel model of psychedelic action called HEALS (Hemispheric Annealing and Lateralization Under Psychedelics) which involves the reversal of the typical hierarchical relationship between the two hemispheres of the...

DOI: 10.1177/02698811241303599 Full text Psychedelics Hallucinogens Lateralization

Pictorial representation of illness and self measure (PRISM): A putative transdiagnostic tool for evaluating therapeutic effects of psychedelic treatments.

Journal of psychopharmacology (Oxford, England) May 1, 2025 Niloufar Pouyan, Jacob S. Aday, Steven E. Harte et al. 1 citation

Patients with refractory conditions often identify themselves with their illness, which affects multiple aspects of their lives. The pictorial representation of illness and self measure (PRISM) is a tool used to assess the enmeshment of individuals' perception of self with a particular medical condition, broadly termed self-condition enmeshment. This study aimed to evaluate changes in PRISM...

DOI: 10.1177/02698811251330763 Full text Psychedelic therapy Naturalistic psychedelic use Self-condition enmeshment Transdiagnostic +4

Commentary: A framework for assessment of adverse events in psychedelic research.

Journal of psychopharmacology (Oxford, England) May 1, 2025 Katherine Cheung, Rebecca Ehrenkranz, Jared T. Hinkle et al. 1 citation

Recent discussions about the methodological rigor of psychedelic clinical trials have focused on potential underreporting or misreporting of adverse events (AEs), with many calling for their systematic assessment to help mitigate these issues. In their recent paper, Palitsky et al. offer a comprehensive framework for the assessment of AEs in psychedelic-assisted therapies, with consideration of...

DOI: 10.1177/02698811241309623 Full text Psychedelics Adverse events Bias Systematic assessment +5

Oral esketamine for patients with severe treatment-resistant depression: Effectiveness, safety, and tolerability of a six-week open-label treatment program.

Journal of psychopharmacology (Oxford, England) April 25, 2025 Jolien Ke Veraart, Sanne Y Smith-Apeldoorn, Annemarie van der Meij et al. 6 citations

Oral esketamine for patients with treatment-resistant depression (TRD) could offer certain advantages over other routes, such as intravenous or intranasal, but it has not been systematically studied in a real-world setting. Here we present results from a relatively large naturalistic study to evaluate the effectiveness, tolerability, and safety of oral esketamine in patients with TRD. One...

DOI: 10.1177/02698811251332831 Full text Treatment-resistant depression Oral esketamine Real-world effectiveness Mental health treatment +1

Peri-traumatic consumption of classic psychedelics is associated with lower anxiety and post-traumatic responses 3 weeks after exposure.

Journal of psychopharmacology (Oxford, England) April 21, 2025 Einat Karp Barnir, Zohar Rubinstein, Rany Abend et al. 7 citations

Emerging evidence indicates the therapeutic potential of psychedelic compounds for post-traumatic stress, yet the mechanisms mediating their effects remain unclear. Delineating the effect of psychedelics on traumatic memory formation could shed light on target therapeutic mechanisms. Here, we report on 343 adult survivors of a single, large-scale terrorist attack taking place during a festival...

DOI: 10.1177/02698811251334025 Full text MDMA LSD Psilocybin Post-traumatic responses +10

Pharmacokinetics and pharmacodynamics of sublingual microdosed lysergic acid diethylamide in healthy adult volunteers.

Journal of psychopharmacology (Oxford, England) April 18, 2025 James D Morse, Soo Hee Jeong, Robin J Murphy et al. 3 citations

Microdosing is the practice of taking psychedelic drugs at doses that produce no or minimal perceptible subjective or behavioural effects. This study investigated the pharmacokinetics and pharmacodynamics of microdosed lysergic acid diethylamide (LSD). This was a Phase 1 double-blind placebo-controlled parallel-groups trial with 80 healthy male volunteers (four withdrawals due to anxiety)....

DOI: 10.1177/02698811251330747 Full text LSD Pharmacodynamics Psychedelics hallucinogens Microdosing sub-perceptual dosing +5

Behavioral effects of three synthetic tryptamine derivatives in rodents.

Journal of psychopharmacology (Oxford, England) April 4, 2025 Rebecca D. Hill, Ritu A. Shetty, Nathalie Sumien et al.

New synthetic tryptamine derivatives have emerged in the underground market. They act on serotonin receptors mimicking the effects of hallucinogenic drugs such as DOM. The DEA has identified three tryptamine derivatives of concern, 5-MeO-DBT, 5-Cl-DMT, and 4-OH-MiPT. Swiss Webster mice were tested for locomotor activity. Discriminative stimulus effects were tested in male Sprague-Dawley rats...

DOI: 10.1177/02698811251330737 Full text Serotonin Drug discrimination Hallucinogens psychedelics Entheogens +4

A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapy.

Journal of psychopharmacology (Oxford, England) April 1, 2025 Leor Roseman 12 citations

The recent rejection of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy by the U.S. Food and Drug Administration (FDA) is a dramatic moment in the re-emergence of psychedelic research. In this perspective, I argue that it represents a case study for paradigmatic tensions within psychopharmacology. The regulatory system is still influenced by a paradigm that sees the therapeutic...

DOI: 10.1177/02698811241309611 Full text Set and setting Psychedelics hallucinogens Entheogens Psychedelic medicine +7

Ayahuasca enhances the formation of hippocampal-dependent episodic memory without impacting false memory susceptibility in experienced ayahuasca users: An observational study.

Journal of psychopharmacology (Oxford, England) April 1, 2025 Manoj K. Doss, Lilian Kloft, Natasha L. Mason et al. 5 citations

Ayahuasca is an Amazonian brew with 5-HT2A-dependent psychedelic effects taken by religious groups globally. Recently, psychedelics have been shown to impair the formation of recollections (hippocampal-dependent episodic memory for specific details) and potentially distort memory while remembering. However, psychedelics spare or enhance the formation of familiarity-based memory...

DOI: 10.1177/02698811241301216 Full text Ayahuasca Episodic memory False memory Familiarity +5

Exploring the impact of MDMA and oxytocin ligands on anxiety and social responses: A comprehensive behavioural and molecular study in the zebrafish model.

Journal of psychopharmacology (Oxford, England) April 1, 2025 Monika Maciag, Olga Doszyn, Artur Wnorowski et al. 4 citations

Mental disorders, including anxiety and depression, impact nearly 1 billion people worldwide. Recent research has highlighted the potential of certain amphetamine compounds in the therapy of psychiatric disorders, with 3,4-methylenedioxymethamphetamine (MDMA) emerging as a promising candidate. This study investigates the effects of MDMA on anxiety and social behaviours using 3-week-old...

DOI: 10.1177/02698811251324596 Full text Molly MDMA Ecstasy Neurotransmitters Oxytocin system +7

Monoamine neurotransmitter-related gene-based genome-wide association study of low-dose ketamine in patients with treatment-resistant depression.

Journal of psychopharmacology (Oxford, England) March 24, 2025 Chung-Feng Kao, Shih-Jen Tsai, Tung-Ping Su et al. 1 citation

Low-dose ketamine is an N-methyl-D-aspartate receptor antagonist that exerts an antidepressant effect on patients with treatment-resistant depression (TRD). This antidepressant effect may extend beyond the glutamatergic hypothesis. Nevertheless, the roles of genes encoding other monoamine neurotransmitters (i.e., serotonin and dopamine) in the neuromechanism of low-dose ketamine remain unknown....

DOI: 10.1177/02698811251326939 Full text Treatment-resistant depression Neurotransmitter studies Psychiatric genomics Antidepressant mechanisms +4

Lifetime classic psychedelic use and headaches: A cross-sectional study.

Journal of psychopharmacology (Oxford, England) March 12, 2025 Zusanna Bjurenfalk, Alva Cosmo, Otto Simonsson et al. 3 citations

Migraine and cluster headache are two primary headache disorders for which conventional treatments are limited. Classic psychedelic substances such as lysergic acid diethylamide (LSD) and psilocybin are potentially promising new treatment candidates for these conditions. The aim of the present study was to investigate the possible relationship between the lifetime use of classic psychedelics...

DOI: 10.1177/02698811251324372 Full text LSD Psilocybin Magic mushrooms Headache disorders migraines +5

Acute subanesthetic ketamine-induced effects on the mismatch negativity and their relationship to early and sustained treatment response in major depressive disorder.

Journal of psychopharmacology (Oxford, England) February 26, 2025 Sara de la Salle, Jennifer L Phillips, Pierre Blier et al. 3 citations

A sub-anesthetic dose of ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, produces robust antidepressant effects in treatment-resistant major depressive disorder (MDD). The mismatch negativity (MMN) is reliant on glutamatergic neurotransmission and reduced by NMDAR antagonists. The MMN may characterise the neural mechanisms underlying ketamine's effects. This study examined the...

DOI: 10.1177/02698811251319456 Full text Major depressive disorder Cortical source density Event-related oscillations Midazolam +6

Impact of psychedelics on craving in addiction: A systematic review.

Journal of psychopharmacology (Oxford, England) February 1, 2025 Sophie-Athéna Chapron, Guilhem Bonazzi, Laura Di Lodovico et al. 5 citations

In the context of the need to increase treatment options for substance use disorders, recent research has evaluated the therapeutic potential of psychedelics. However, there is an incomplete understanding of psychedelics' effects on craving, a core symptom of addictive disorders and a predictor of substance use and relapse. To determine if the use of psychedelics is associated with changes in...

DOI: 10.1177/02698811241308613 Full text Addiction Psychedelics Craving Hallucinogens +2

Is there a risk of addiction to ketamine during the treatment of depression? A systematic review of available literature.

Journal of psychopharmacology (Oxford, England) 2025 Gianmarco Ingrosso, Anthony J. Cleare, Mario F Juruena 20 citations

Ketamine has demonstrated both rapid and sustained efficacy in treating depression, especially in treatment-resistant cases. However, concerns regarding the addictive potential of ketamine during long-term depression treatment persist among clinicians. This review aimed to summarise the evidence on addiction phenomena associated with ketamine treatment of depression. A comprehensive search was...

DOI: 10.1177/02698811241303597 Full text Dependence Esketamine Ketamine therapy Depression treatment +3

Papers